FDA approves new epinephrine injector from Adamis Pharmaceuticals
The U.S. Food & Drug Administration (FDA) has finally approved a new epinephrine injector for anaphylaxis, increasing competition for the controversially expensive injector EpiPen.
Symjepi, the new epinephrine injector made by Adamis Pharmaceuticals Corp., is a syringe prefilled with the epinephrine hormone, which is capable of stopping life-threatening allergic reactions from insect stings, foods like eggs and certain medications.
Accordiing to San Diego-based Adamis, its new product is easier to use than EpiPen that comes filled with a set dose and is accompanied by a training device.
In addition, Symjepi will be easier to carry as it is notably smaller than EpiPen. Most kids and adults with severe allergies have to carry an injector wherever they go.
Evercore ISI analyst Umer Raffat and some others have pointed out that Symjepi isn’t totally identical to EpiPen; so its price will definitely be a key consideration.
Currently, Mylan Pharmaceuticals’ EpiPen costs in the range of $630 to $700 without insurance. The new generic version retails for around $225 to $425.
The People’s Party (ÖVP) has won the parliamentary elections and 31-year-old leader Sebastian Kurz would be the youngest national leader in Europe. Kurz will be having a tough task of dealing with European leadership.
IBM is using blockchain for improving speed and security for cross-border transactions. The solution offered by IBM is focused on banking sector.
Tesla Motors has fired hundreds of employees after annual performance review. The company confirmed the move but the management hasn’t mentioned the exact number of employees fired during the current performance review.
Tesla Motors has announced recall of 11,000 Model X vehicles to fix a seat cable issue. The voluntary recall involves Model X SUVs manufactured between October 28, 2016 and August 16, 2017.
Norway is planning to add additional tax burden on consumers planning to buy electric cars.
German government has raised the growth outlook for 2017 to two percent from earlier estimate of 1.5 percent. The growth outlook for 2018 has been raised to1.9 percent from earlier estimate of 1.6 percent.